DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Gahrton
G
G
Department of Medicine, Huddinge Hospital, Sweden.
Tidefelt
U
U
Paul
C
C
Björkholm
M
M
Grimfors
G
G
Hast
R
R
Juliusson
G
G
Järnmark
M
M
Killander
A
A
Kimby
E
E
D000293:Adolescent; D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004247:DNA / Q000627:therapeutic use*; D018736:DNA Adducts; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D018736:DNA Adducts; C031902:doxorubicin-DNA; D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D004247:DNA; D011239:Prednisolone; D015122:Mercaptopurine; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin